Opinion|Videos|February 4, 2025
Best Practices for HLA and MAGE-A4 Testing
A panelist discusses how the main challenges in MAGE-A4 testing include optimizing the timing of both human leukocyte antigen (HLA) and MAGE-A4 expression testing, establishing standardized testing protocols across institutions, and ensuring adequate tissue availability for testing, while recommending early screening at diagnosis or first relapse to allow sufficient time for treatment planning if patients become eligible.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- When testing for MAGE-A4 expression, what challenges do you anticipate in identifying eligible patients?
- When are you testing for HLA and MAGE-A4, and what do you recommend to your colleagues?
Advertisement
Related to this article
UTRxMYCN M1-14 received orphan drug status for soft tissue sarcoma and RPDD for rhabdomyosarcoma.
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
Denosumab-adet (Degevma) is FDA-approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and hypercalcemia of malignancy.
The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
R. Lor Randall, MD, FACS, outlines how AI may affect oncology training, how to properly work alongside AI, and AI-patient conversations.
R. Lor Randall, MD, FACS, discusses AI in musculoskeletal tumor diagnosis, surgical planning and robotics, and validation of AI tools.
SOT106 now holds both orphan drug and fast track designations across soft tissue sarcoma and osteosarcoma ahead of a first-in-human trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC
3
Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC
4
FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC
5